Table 1.
Frequent molecular alterations in the most common histologic subtypes of ovarian cancer.
| Histologic Subtype | Frequent Molecular Alterations |
Available Targeted Therapies |
|---|---|---|
| Epithelial Tumors | ||
| High grade serous carcinoma | TP53, BRCA1, BRCA2, HRR deficiency | PARP inhibitors (1) |
| Low grade serous carcioma | KRAS, BRAF, NRAS, PIK3CA, ERBB2, PTEN, CTNNB1, ER/PR positive | MEK inhibitors (2) Fulvestrant (2) Hormonal therapy (2) |
| Clear cell carcinoma | PIK3CA, ARID1A | None |
| Endometrioid carcinoma | CTNNB1, ARID1A, PIK3CA | None |
| Mucinous carcinoma | KRAS, ERBB2 | None |
| Germ Cell Tumors | Karyotypic abnormalities | |
| Dysgerminoma | KIT, DICER1, TP53, KRAS | None |
| Yolk sac tumor | KRAS, PIK3CA | None |
| Sex-Cord Stromal Tumors | DICER1 | None |
| Granulosa cell tumors | FOXL2, ER/PR positive | Aromatase inhibitors (2) Leuprolide (2) |
| Histology Agnostic | ||
| TMB-H | Pembrolizumab (1) | |
| MSI-H dMMR |
Pembrolizumab (2) Dostarlimab (2) |
|
| NTRK fusions | Larotrectinib (2) Entrectinib (2) |
Legend: (1) FDA approved targeted therapy. (2) NCCN guidelines recommended targeted therapy. HRR, homologous recombination repair; ER, estrogen receptor; PR, progesterone receptor; MEK, mitogen activated protein kinase; NTRK, neurotrophic tyrosine receptor kinases